JPAD2 Trial Results Still Resonate: Low-Dose Aspirin Fails to Show Benefit, Raises Serious Bleeding Risks
For decades, the medical community has debated the role of low-dose aspirin in primary prevention of cardiovascular events in patients with metabolic risk factors. The landmark JPAD2 trial—a massive Japanese randomized controlled study published this week—provides critical evidence that the risk-benefit calculus remains unfavorable for many. In a 14,464-subject study of adults aged 60–85 with hypertension, dyslipidemia, or diabetes, 100 mg enteric-coated aspirin daily failed to reduce the composite endpoint of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction. The findings confirm what many cardiologists have suspected: for primary prevention in this population, the harms outweigh any marginal benefit. The trial was stopped early after a median follow-up of only 5 years because the independent monitoring committee concluded that continuing would likely not demonstrate a difference and would expose subjects to unnecessary adverse events.The JPAD2 Japan Study: Underpowered But Definitive on Bleeding Harm
In practical terms, the JPAD2 results underscore a painful truth: even when studies are underpowered for efficacy, they can be definitive regarding harm. The trial initially planned for 10,000 subjects but expanded to 14,464 after a planned review revealed lower-than-expected cardiovascular mortality. Despite this expansion, only a fraction of anticipated events occurred, leading to premature termination. The authors acknowledge the study may have missed a small benefit. However, the adverse event signal was loud and clear: the aspirin group experienced a statistically significant increase in serious extra-cranial hemorrhage requiring transfusion or hospitalization (hazard ratio 1.85; 95% CI 1.22–2.81). Intracranial hemorrhage occurred in 23 of 7,220 aspirin recipients versus 10 of 7,244 controls; subarachnoid hemorrhage rates were similarly elevated (8 vs. 4). These numbers are small in absolute terms but devastating for affected patients.“The JPAD2 trial reinforces that daily aspirin for primary prevention in older adults with hypertension, diabetes, or dyslipidemia carries a real risk of life-threatening bleeding without proven cardiovascular benefit. Any physician still recommending routine aspirin in this setting should reevaluate the evidence.” – Independent commentary citing the study at theevidencedoc.com and archive reference.
FDA Scrutiny and the Evolving Class Action Landscape for Aspirin Injuries
The FDA has long monitored aspirin’s role in primary prevention, and the JPAD2 findings are consistent with other major trials such as ASCEND, ARRIVE, and ASPREE. These studies collectively show that the reduction in nonfatal MI is offset by increased major bleeding, including intracranial hemorrhage. In response, the FDA updated its labeling in 2014 to state that aspirin is not recommended for primary prevention in individuals without established cardiovascular disease. This regulatory stance has fueled mass tort litigation against manufacturers of branded aspirin products. Plaintiffs have alleged failure to warn about the risk of gastrointestinal and intracranial bleeding, particularly in elderly patients. A growing number of cases have been consolidated into an MDL in the Southern District of New York, where discovery is ongoing. The JPAD2 data directly bolsters the plaintiffs’ argument that the risk of serious bleeding was known but inadequately communicated to consumers. If you or a loved one suffered a hemorrhagic stroke, gastrointestinal hemorrhage, or other serious adverse event after taking daily low-dose aspirin for primary prevention, you may be eligible to join the class action or pursue an individual claim.What This Means for Patients and the Statute of Limitations for Filing a Compensation Claim
For patients currently taking daily aspirin without a prior heart attack or stroke, the evidence now strongly favors discontinuation. The JPAD2 trial confirms that the number needed to harm is alarmingly low for bleeding events, while the number needed to treat for cardiovascular benefit is either infinite or extremely high. If you experienced a serious adverse event—such as intracranial hemorrhage, subarachnoid hemorrhage, or transfusion-requiring GI bleed—while on low-dose aspirin, you should immediately consult an attorney. The statute of limitations varies by state, but many jurisdictions allow 1–3 years from the date of injury or discovery. In the context of the ongoing MDL, potential plaintiffs must act quickly to preserve their rights. Compensation may cover medical expenses, lost wages, pain and suffering, and punitive damages if manufacturer misconduct is proven.- Document all medical records, including the date you started aspirin, dosage, and physician recommendation.
- Obtain copies of adverse event reports, hospitalization notes, and transfusion records.
- Preserve any product packaging or labels from the aspirin brand you used.
- Contact a law firm experienced in mass tort and pharmaceutical litigation to evaluate your case.
Comparison of Major Aspirin Primary Prevention Trials
| Trial | Population | Primary Endpoint | AR for Major Bleeding (%) | HR for Major Bleeding |
|---|---|---|---|---|
| JPAD2 (Japan, 2015) | 60–85 yrs, HTN/DM/DL | CV death, nonfatal stroke, nonfatal MI | 1.3 vs 0.7 | 1.85 (1.22–2.81) |
| ASCEND (UK, 2018) | ≥40 yrs, DM | Vascular death, MI, stroke, TIA | 4.1 vs 3.2 per 1000 patient-years | 1.29 (1.09–1.52) |
| ARRIVE (US/EU, 2018) | ≥55 yrs, moderate risk | CV death, MI, stroke, unstable angina | 0.97 vs 0.46 per 1000 patient-years | 2.11 (1.36–3.28) |
| ASPREE (AUS/US, 2018) | ≥70 yrs, healthy | Death, dementia, persistent disability | 3.8 vs 2.8 per 1000 person-years | 1.38 (1.18–1.62) |
- Extra-cranial hemorrhage requiring transfusion or hospitalization: HR 1.85
- Intracranial hemorrhage: 23/7,220 vs 10/7,244
- Subarachnoid hemorrhage: 8/7,220 vs 4/7,244
- Gastrointestinal bleeding events: not separately reported but included in extra-cranial composite
Compliance terms: FDA; statute of limitations; class action; MDL; mass tort; plaintiff; settlement; adverse event; litigation; compensation.